Fabtech Technologies Limited is a global engineering company based in Mumbai. The company builds and installs “turnkey” (ready-to-use) cleanroom and process equipment solutions for pharmaceutical, biotech, and healthcare industries. That means Fabtech helps set up the entire special “clean” working area, from design to all equipment and air/water systems needed by pharma factories and labs. Fabtech has delivered major projects in over 62 countries, including places like Saudi Arabia, Egypt, Sri Lanka, UAE, and more.
READ FULL DRHP HERE: |SEBI DRHP FABTECH |
IPO Details
| Details | Information |
|---|---|
| IPO Opening Date | September 29, 2025 |
| IPO Closing Date | October 1, 2025 |
| Listing Date | October 7, 2025 |
| IPO Price Band | ₹181 - ₹191 per share |
| Minimum Lot Size | 75 shares (about ₹14,325 at highest price) |
| Issue Size | ₹230.35 crore (fully fresh issue) |
| Face Value | ₹10 per share |
| Stock Exchanges | NSE, BSE (Mainboard IPO) |
| Book-Running Lead Manager | Unistone Capital Pvt Ltd |
| Registrar | Bigshare Services Pvt Ltd CLICK HERE |
IPO Timeline (Important Dates)
| Event | Date |
|---|---|
| IPO Opens | September 29, 2025 |
| IPO Closes | October 1, 2025 |
| Basis of Allotment | October 3, 2025 |
| Refunds/Unsuccessful Bids | October 6, 2025 |
| Shares in Demat Account | October 6, 2025 |
| Listing Date | October 7, 2025 |
What Will the IPO Money Be Used For?
- Day-to-day working capital for the business
- Business expansion through new acquisitions (buying other companies)
- General company needs
Key Financials
| Metric | FY23 (₹ Cr) | FY24 (₹ Cr) |
|---|---|---|
| Revenue | 328.8 | 411.2 |
| Profit After Tax (PAT) | 24.8 | 30.06 |
| EBITDA (Operating Profit) | 40.7 | 47.3 |
| Net Worth (Equity Capital) | 131.9 | 173.1 |
| Reserves & Surplus | 128.9 | 140.7 |
| Borrowings | 54.6 | 46.5 |
| EBITDA Margin | 12.3% | 11.5% |
| PAT Margin | 7.5% | 7.3% |
Financials Explanation
- Revenue is total money from sales
- EBITDA is profit from main operations (before taxes and interest)
- PAT is the company’s final profit after all costs and taxes
- Net Worth shows what owners and investors have in the business
- Borrowings means money owed to banks or other lenders
- Margins (EBITDA, PAT) show what share of money is kept as profit.
ANALYSIS:
-
Revenue has jumped to 44% in one year, showing that the business is growing fast.
-
Fabtech’s PAT increased from ₹27.22 crore in FY24 to ₹46.45 crore in FY25 (up 71% year-over-year).
-
EBITDA was ₹39.75 crore in FY24 and rose to ₹47.28 crore in FY25 (about 19% increase).
-
Fabtech’s ROE jumped from 24.65% in FY24 to 30.46% in FY25, which means the company is giving strong returns to its shareholders.
-
ROCE moved from 28.76% in FY24 to 24.46% in FY25. This small drop means a little less efficiency, possibly due to higher borrowings to grow the business.
-
Debt-to-equity increased from just 0.07 in FY24 to 0.32 in FY25 (still conservative), showing that Fabtech borrowed more to expand but remains low-risk on debt.
-
Net Worth (owner’s equity): ₹173.1 crore in FY25, up from ₹131.9 crore.
-
Total Borrowing: ₹54.62 crore in FY25 versus ₹9.88 crore in FY24.
-
Assets: The company has assets worth ₹426.56 crore by FY25.
Why do some investors like this IPO?
- Specialist in global pharma/biotech infrastructure—a niche, growing export market
- Turnkey solution company, not just a manufacturer
- Revenue and profit have been steadily rising in the last two years
- Known brand among pharma equipment and cleanroom players
Points that need caution:
- Business depends on pharma industry growth and large project orders
- Project business can have big ups/downs—sometimes a lot of orders, sometimes fewer
- Exports mean some risk from currency fluctuations
- High engineering skill required and a lot of competition